Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding

S Jacobitz, MM McLaughlin, GP Livi, M Burman and TJ Torphy

Department of Pharmacology, Smithkline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA.

To identify functional domains of the 886-amino acid human recombinant cAMP-specific phosphodiesterase (PDE) subtype A (rhPDE4A), we engineered the expression of seven mutant proteins containing both NH2- and COOH-terminal truncations. The level of rhPDE4A protein expression in yeast was monitored by immunoblotting using enzyme-specific antisera. Biochemical profiles of the mutant proteins were compared with those of the full-length protein or a fully active truncated form of the enzyme (rhPDE4A Met265-886), lacking the first 264 amino acids. The smallest catalytically active fragment generated was Met332-722, which at 45 kDa is less than half the mass of the full-length enzyme (approximately 110 kDa) but spans the most highly conserved region of the PDE superfamily. Two prototypical PDE4 inhibitors, rolipram and RP 73401, inhibited cAMP hydrolyzing activity of all truncated forms of the enzyme, with IC50 values of 70-2000 nM and 0.2-0.6 nM, respectively. [3H](R)-Rolipram bound to two sites on Met265-886, a high affinity site (Kd1 = 0.7 +/- 0.3 nM) and a low affinity site (Kd2 = 34 +/- 10 nM). Interestingly, [3H](R)-rolipram failed to bind to Met332- 886 with high affinity, indicating that high affinity binding is not required for inhibition of enzyme activity. Low affinity rolipram binding was still present in Met332-886 (Kd = 101 +/- 7 nM). In contrast to [3H](R)-rolipram, [3H]RP 73401 bound to a single class of high affinity sites on Met265-886 (Kd = 0.4 +/- 0.1 nM). Further truncation of the enzyme to Met332-886 had no effect on [3H]RP 73401 binding (Kd = 0.2 +/- 0.03 nM). We conclude that the catalytic center of rhPDE4A lies between amino acids 332 and 722. Furthermore, amino acids 265-332 may form a high affinity binding site for rolipram that is outside of the catalytic domain. As a more likely alternative, these amino acids may not form a distinct binding site but instead may be required for the recombinant enzyme to assume a conformation that binds rolipram at the catalytic domain with a high affinity.

Volume 50, Issue 4, pp. 891-899, 10/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. A. Blount, R. Zoraghi, E. P. Bessay, A. Beasley, S. H. Francis, and J. D. Corbin Conversion of Phosphodiesterase-5 (PDE5) Catalytic Site to Higher Affinity by PDE5 Inhibitors J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 730 - 737. [Abstract] [Full Text] [PDF]

				N. K. Charlie, A. M. Thomure, M. A. Schade, and K. G. Miller The Dunce cAMP Phosphodiesterase PDE-4 Negatively Regulates G{alpha}s-Dependent and G{alpha}s-Independent cAMP Pools in the Caenorhabditis elegans Synaptic Signaling Network Genetics, May 1, 2006; 173(1): 111 - 130. [Abstract] [Full Text] [PDF]

				R. Zoraghi, J. D. Corbin, and S. H. Francis Properties and Functions of GAF Domains in Cyclic Nucleotide Phosphodiesterases and Other Proteins Mol. Pharmacol., February 1, 2004; 65(2): 267 - 278. [Full Text] [PDF]

				Y. Zhao, H.-T. Zhang, and J. M. O'Donnell Antidepressant-Induced Increase in High-Affinity Rolipram Binding Sites in Rat Brain: Dependence on Noradrenergic and Serotonergic Function J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 246 - 253. [Abstract] [Full Text] [PDF]

				Y. Zhao, H.-T. Zhang, and J. M. O'Donnell Inhibitor Binding to Type 4 Phosphodiesterase (PDE4) Assessed Using [3H]Piclamilast and [3H]Rolipram J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 565 - 572. [Abstract] [Full Text] [PDF]

				W. Zhang, H. Ke, and R. W. Colman Identification of Interaction Sites of Cyclic Nucleotide Phosphodiesterase Type 3A with Milrinone and Cilostazol Using Molecular Modeling and Site-Directed Mutagenesis Mol. Pharmacol., September 1, 2002; 62(3): 514 - 520. [Abstract] [Full Text] [PDF]

				S. B. Herman, D. M. Juilfs, E. B. Fauman, P. Juneau, and J. P. Menetski Analysis of a Mutation in Phosphodiesterase Type 4 that Alters Both Inhibitor Activity and Nucleotide Selectivity Mol. Pharmacol., May 1, 2000; 57(5): 991 - 999. [Abstract] [Full Text]

				E. Boichot, J. L. Wallace, N. Germain, M. Corbel, C. Lugnier, V. Lagente, and J.-J. Bourguignon Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9-Benzyladenine J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 647 - 653. [Abstract] [Full Text]

				C. Méhats, G. Tanguy, B. Paris, B. Robert, N. Pernin, F. Ferré, and M.-J. Leroy Pregnancy Induces a Modulation of the cAMP Phosphodiesterase 4-Conformers Ratio in Human Myometrium: Consequences for the Utero-Relaxant Effect of PDE4-Selective Inhibitors J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 817 - 823. [Abstract] [Full Text]

				J. Lim, G. Pahlke, and M. Conti Activation of the cAMP-specific Phosphodiesterase PDE4D3 by Phosphorylation. IDENTIFICATION AND FUNCTION OF AN INHIBITORY DOMAIN J. Biol. Chem., July 9, 1999; 274(28): 19677 - 19685. [Abstract] [Full Text] [PDF]

				I. McPhee, S. J. Yarwood, G. Scotland, E. Huston, M. B. Beard, A. H. Ross, E. S. Houslay, and M. D. Houslay Association with the SRC Family Tyrosyl Kinase LYN Triggers a Conformational Change in the Catalytic Region of Human cAMP-specific Phosphodiesterase HSPDE4A4B. CONSEQUENCES FOR ROLIPRAM INHIBITION J. Biol. Chem., April 23, 1999; 274(17): 11796 - 11810. [Abstract] [Full Text] [PDF]

				J. M. Atienza, D. Susanto, C. Huang, A. S. McCarty, and J. Colicelli Identification of Inhibitor Specificity Determinants in a Mammalian Phosphodiesterase J. Biol. Chem., February 19, 1999; 274(8): 4839 - 4847. [Abstract] [Full Text] [PDF]

				D. E. Griswold, E. F. Webb, A. M. Badger, P. D. Gorycki, P. A. Levandoski, M. A. Barnette, M. Grous, S. Christensen, and T. J. Torphy SB 207499 (Ariflo), a Second Generation Phosphodiesterase 4 Inhibitor, Reduces Tumor Necrosis Factor alpha  and Interleukin-4 Production in vivo J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 705 - 711. [Abstract] [Full Text]

				I. V. Turko, S. H. Francis, and J. D. Corbin Potential Roles of Conserved Amino Acids in the Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5) J. Biol. Chem., March 13, 1998; 273(11): 6460 - 6466. [Abstract] [Full Text] [PDF]

				M. S. Barnette, S. B. Christensen, D. M. Essayan, M. Grous, U. Prabhakar, J. A. Rush, A. Kagey-Sobotka, and T. J. Torphy SB 207499 (Ariflo), a Potent and Selective Second-Generation Phosphodiesterase 4 Inhibitor: In Vitro Anti-inflammatory Actions J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 420 - 426. [Abstract] [Full Text]

				S. Jacobitz, M. D. Ryan, M. M. McLaughlin, G. P. Livi, W. E. Dewolf Jr., and T. J. Torphy Role of Conserved Histidines in Catalytic Activity and Inhibitor Binding of Human Recombinant Phosphodiesterase 4A Mol. Pharmacol., June 1, 1997; 51(6): 999 - 1006. [Abstract] [Full Text]

				T. J. TORPHY Phosphodiesterase Isozymes . Molecular Targets for Novel Antiasthma Agents Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 351 - 370. [Full Text]